A year-and-a-half after graduating from college in 1999, the last thing that Steve Smith, now 25, expected was for his kidneys to fail. Although the Nashville resident had always been active and healthy and had no family history of kidney disease, shortly after moving to Los Angeles, he began experiencing what he describes as "strange symptoms" that he thought might be associated with mononucleosis. When he went to the doctor, he learned that his kidneys had failed.
He moved back to Nashville and received his first kidney transplant in May, 2000, but his body developed high antibodies and rejected the organ seven months later. Worse still, because of the high antibodies, it was unlikely that doctors would be able to find another match for him as his body would very likely see another donor kidney as a foreign intruder and reject it.
However, neither Smith nor his physicians were willing to give up. His doctors had heard of an innovative kidney transplant therapy that was developed at Cedars-Sinai Medical Center in Los Angeles. They told Smith about it, and he went online to do additional research. He learned that the therapy, known as intravenous immunoglobulin (IVIG) makes kidney transplantation possible between donors and recipients who previously would have been considered poor matches. Smith learned that a new test could help determine which patients were most likely to benefit.
IVIG therapy, which has been used for several years for other diseases, was adapted for use in the field of transplantation by researchers led by Stanley C. Jordan, M.D., medical director of Cedars-Sinais Kidney Transplant Program, director of Pediatric Nephrology and Transplant Immunology, and professor of pediatrics at the University of California, Los Angeles. In September, 2002, Smith traveled to Los Angeles where he was seen by Dr. Jordan.
After successfully undergoing the new test to determine whether the IVIG therapy would prove effective for Smith, his donor-friend also flew to Los Angeles for additional testing. The results showed that the therapy would likely be effective in Smiths case, so the transplant was scheduled for a couple of weeks later.
Prior to the transplant, Smith received two, four-hour treatments of IVIG therapy - an intravenous drip while he was on dialysis. About a month after his transplant, he received a final treatment with IVIG.
"I feel good!" he says now. "The blood test scores are great. I just took my donor on a cruise and Im trying to get my life back on track."
Just a few years ago, Smith would have been facing a lifetime of kidney dialysis and little hope for a transplant. Thanks to these new medical advances, though, he has moved back to Los Angeles to resume his career in the entertainment industry.
Coming at a time when the waiting list for cadaveric kidneys is predicted to climb to 100,000 patients by 2006 and 150,000 by 2010, these new techniques may result in greater access to transplantation for many patients who otherwise would have had little hope. In fact, a study published by Dr. Jordan in the American Journal of Transplantation in 2002, showed that the procedure appears to dramatically increase success for patients receiving cadaver organs as well as those receiving kidneys from living relatives or friends.
The infusion of IVIG has been used for several years to help prevent rejection, even in difficult cases when other anti-rejection methods have failed. While most anti-rejection medications suppress the immune system entirely, thereby increasing the patients risk of infection, IVIG appears to control immune responses that would harm a transplanted organ, while boosting protection from infection.
Dr. Jordan and his team have now fine-tuned their techniques in the laboratory to predict which patients would most likely benefit from IVIG. By introducing IVIG into the analysis, they are able to make poor matches much more compatible.
The process of "crossmatching" is performed by combining a sample of the potential recipients blood serum with a sample of the potential donors white cells. The question of compatibility revolves around human leukocyte antigen (HLA), proteins that regulate the way the body recognizes foreign substances.
If the recipient has developed antibodies to the donors HLA, the antibody attacks the antigen as an invader. This is called a "positive" crossmatch and it indicates that the recipients immune system would reject the donors organ. The potential recipient is said to be "sensitized" to the donors HLA. If the recipient does not have antibodies against the donors HLA - a negative crossmatch - this reaction does not occur.
Because highly sensitized patients have comparatively high risks of rejection and low organ-survival success rates, transplants for these patients have decreased drastically in the past 15 years. Further, there have been no therapies available to resolve issues of immune incompatibility, leaving most patients to rely on dialysis for extended periods of time in the hope that a well-matched kidney might become available.
But Dr. Jordan and his colleagues showed that adding IVIG during the crossmatch process in the laboratory inhibited the destruction of incompatible HLA-bearing cells, in most cases, essentially changing a positive crossmatch to a negative one. Subsequently, patients were able to receive IVIG therapy and undergo a transplant, if the crossmatch became negative after IVIG treatment.
"Based on our results, the IVIG crossmatch technique is a very effective predictor of the way IVIG will help a patients immune system to accept a transplanted organ," said Dr. Jordan. "Those who have a good response in the laboratory can be given IVIG, which eliminates the positive crossmatch and allows for successful transplantation, in most cases. Therefore, a positive crossmatch does not necessarily mean that a patient cannot receive a transplant."
Cedars-Sinai Medical Center is one of the largest nonprofit academic medical centers in the Western United States. For the fifth straight two-year period, it has been named Southern Californias gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. Named one of the 100 "Most Wired" hospitals in health care in 2001, the Medical Center ranks among the top 10 non-university hospitals in the nation for its research activities.
Sandy Van | Van Communications
A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital
Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München
More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.
Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...
Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.
"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...
The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.
Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...
The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...
Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.
Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...
20.04.2017 | Event News
18.04.2017 | Event News
03.04.2017 | Event News
24.04.2017 | Physics and Astronomy
24.04.2017 | Materials Sciences
24.04.2017 | Life Sciences